By Jim Fink:
Here's an important trend in the investment world right now: the recent buyouts of small-cap biotech companies like Idenix (NASDAQ: IDIX) and Intermune (NASDAQ: ITMN). Why so many pharma deals?
Merck (NYSE:MRK), one of the largest...
By Matthew Finston:
Klarman Did What??
Hedge fund manager, Seth Klarman, recently took a 14.06% stake in Veritiv Corp (NYSE:VRTV) for his fund Baupost. Klarman is notorious for bringing an average annual return of 19% for his fund and doing...
By John Vincent:
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's U.S. stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/14/2014. Please visit our...
ByPrescient Investment Analysis:
Gilead Sciences (NASDAQ:GILD) is one of the more compelling companies on the market. Anyone who is familiar with the company is aware that Sovaldi is hailed as a cure for hepatitis C, and prevents the need for...
WHITEHOUSE STATION (dpa-AFX) - Healthcare giant Merck & Co. Inc. (MRK)
Tuesday announced the successful completion of the tender offer for all shares
of Idenix Pharmaceuticals, Inc. (IDIX) at a purchase price of $24.50 per share.
As of the tender...
Here's the list of our Outstanding Performance Award Winners to date. We will be updating weekly:
Winners on July 28, 2014
Unconventional Capital Wisdom - Long IDIX (Idenix Pharmaceuticals), July 30,
Complete Story »
Congratulations to our first two Outstanding Performance award winners:
Winner #1: IDIX (Idenix Pharmaceuticals) by Unconventional Capital Wisdom, July 30, 2013. +597%
Winner #2: FNHC (Federated National Holdings Company) by Nitor Capital,...
Track how today's Stocks To Watch are performing here. To send in your own ideas for next week's Stocks To Watch, email email@example.com before 6:00 AM ET Monday.
Idenix Pharmaceuticals (
) - long -
The hepatitis C industry has been on fire since Merck (NYSE: MRK) paid a 230 percent premium for pharmaceutical company Idenix (NASDAQ: IDIX).
Benzinga spoke to Enanta (NASDAQ: ENTA) CEO Jay Luly about possibilities for his firm, which has one...
Merck (NYSE: MRK) paid a 230 percent premium for Hepatitis C-focused Idenix Pharmaceuticals (NASDAQ: IDIX). News of the massive acquisition, earlier this month, sent shares of other Hep C companies, Enanta (NASDAQ: ENTA) and Achillion (NASDAQ:...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.